Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBk. Cyprus Hldg Regulatory News (BOCH)

Share Price Information for Bk. Cyprus Hldg (BOCH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 355.00
Bid: 350.00
Ask: 354.00
Change: 8.00 (2.31%)
Spread: 4.00 (1.143%)
Open: 350.00
High: 355.00
Low: 346.00
Prev. Close: 347.00
BOCH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement for sale of portf. of Non Perform. Loans

18 Jan 2021 07:00

RNS Number : 9830L
Bank of Cyprus Holdings PLC
18 January 2021
 

Announcement

 

Agreement for sale of a portfolio of Non Performing Loans

 

Nicosia, 18 January 2021

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014.

 

 

Further to the agreement for the sale of Non Performing Loans announced on 3 August 2020 ("Helix 2 Portfolio A"), Bank of Cyprus Holdings Public Limited Company ("BOC Holdings" and, together with its subsidiaries, the "Group") has reached agreement with funds affiliated with Pacific Investment Management Company LLC ("PIMCO"), for the sale of an additional portfolio of Non Performing Loans ("Portfolio B") with a gross book value of €545 mn1,2 (known as "Helix 2 Portfolio B", or the "Transaction").

 

Portfolio B had a contractual balance of €783 mn3 and comprises c.16,000 loans, mainly to Retail and SME clients, secured over c.4,000 real estate collaterals. The net book value of the assets being sold amounts to €244 mn1. The gross consideration amounts to 44%1 of the gross book value and 31%3 of the contractual balance payable in cash, of which 50% is payable at completion and the remaining 50% is deferred up to December 2025 without any conditions attached. The consideration can be increased through an earnout arrangement, depending on the performance of Portfolio B.

 

The Transaction represents another milestone in the delivery of one of the Group's core strategic objectives of improving asset quality through the reduction of NPEs. The Transaction reduces the stock of NPEs by 22%1,4. Overall, the pro forma NPE reduction for 2020 amounted to c.€2.1 bn4 reducing NPEs to €1.8 bn4 and the NPE ratio to 16%4, including Helix 2 (Portfolios A and B) and an organic NPE reduction of c.€600 mn.

 

At completion, the Transaction is expected to be broadly neutral1 to the Group's capital ratios. Upon the payment of the deferred consideration and without taking account of any positive impact from the earnout, the Transaction is expected to have a 14 bps1 positive capital impact on the Group's CET1 ratio. The loan credit losses on Portfolio B, expected to be recorded in 4Q2020, is estimated at c.€27 mn.

 

The completion of Helix 2 Portfolio B will be aligned with the completion of Helix 2 Portfolio A and is currently estimated to occur early in 2H2021. The completion remains subject to a number of conditions, including customary regulatory and other approvals.

 

Following a transitional period where servicing will be retained by the Bank, it is intended that the servicing of both Portfolios will be carried out by a third party servicer selected and appointed by the purchaser.

 

PIMCO is one of the world's premier fixed income investment managers. With its launch in 1971 in Newport Beach, California, PIMCO introduced investors to a total return approach to fixed income investing. In the 45+ years since, the firm continued to bring innovation and expertise to their partnership with clients seeking the best investment solutions. Today PIMCO has offices across the globe and 2,900+ professionals united by a single purpose: creating opportunities for investors in every environment. PIMCO is owned by Allianz SE, a leading global diversified financial services provider.

 

 

Panicos Nicolaou, Group Chief Executive Officer, commented:

 

"I am pleased to announce the signing of the disposal of the Helix 2 Portfolio B today, another milestone in our de-risking strategy.

 

Despite the on-going challenging market conditions, the Bank has signed the sale of €1.4 bn1 NPEs in the last six months (Helix 2 Portfolios A and B). Our combined de-risking actions have reduced NPEs in the year 2020 by c.€2.1 bn4, from €3.9 bn to €1.8 bn4, and the NPE ratio from 30% to 16%4.

 

Overall, since the peak in 2014, we have now reduced the stock of NPEs by €13.2 bn4 or 88%4 and the NPE ratio by 47 percentage points4, from 63% to 16%4.

 

As part of our broader strategic objectives to drive shareholder value creation as set out with our medium term strategic targets announced with our financial results for the nine months ended 30 September 2020, we remain committed to further de-risking the balance sheet and we will continue to seek solutions, both organic and inorganic, to achieve our target of a single digit NPE ratio by the end of 2022. We will continue to assess the potential to accelerate the decrease in NPEs on our balance sheet through additional sales of NPEs in the future.

 

We are now better positioned to manage the challenges resulting from the impact of the on-going COVID-19 crisis, and to support the recovery of the Cypriot economy".

 

 

 

Morgan Stanley & Co. International plc and KPMG LLP acted as financial advisors, Allen & Overy LLP acted as English legal advisors and Chryssafinis & Polyviou LLC acted as Cypriot legal advisors to the Bank in this Transaction.

 

For further information, please contact Investor Relations at investors@bankofcyprus.com.

 

 

 

 

1 Based on the Group Financial Results for the nine months ended 30 September 2020.

2 On balance sheet gross book value of which €529 mn1 relate to non-performing exposures or "NPEs". The gross book value of €545 mn1 includes properties of €9 mn1 that will also be transferred to the buyer.

3 As at the portfolio reference date of 30 September 2019.

4 Calculations on a pro forma basis assume legal completion of both Helix 2 Portfolio A and Helix 2 Portfolio B.

 

 

 

 Group Profile

 

The Bank of Cyprus Group is the leading banking and financial services group in Cyprus, providing a wide range of financial products and services which include retail and commercial banking, finance, factoring, investment banking, brokerage, fund management, private banking, life and general insurance. The Bank of Cyprus Group operates through a total of 98 branches in Cyprus, of which 14 operate as cash offices. Bank of Cyprus also has representative offices in Russia, Ukraine and China. The Bank of Cyprus Group employs 3,577 staff worldwide. At 30 September 2020, the Group's Total Assets amounted to €21.5 bn and Total Equity was €2.1 bn. The Bank of Cyprus Group comprises Bank of Cyprus Holdings Public Limited Company, its subsidiary Bank of Cyprus Public Company Limited and its subsidiaries.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBPMFTMTIBMRB
Date   Source Headline
9th May 20247:00 amRNSBOCH - Transactions in Own Shares
8th May 20247:06 amRNSTransaction in Own Shares
2nd May 20247:28 amRNSBOCH - Transactions in Own Shares
2nd May 20247:20 amRNSBOCH – Total voting rights and Capital
30th Apr 202410:19 amRNSAppointments of New Directors
30th Apr 20247:02 amRNSTransaction in Own Shares
29th Apr 20247:15 amRNSBOCH - Transactions in Own Shares
26th Apr 20241:21 pmRNSDate of announcement of 1Q2024 FR
26th Apr 20247:03 amRNSBOCH - Transactions in Own Shares
25th Apr 20247:26 amRNSBOCH - Transactions in Own Shares
25th Apr 20247:00 amRNSIssue of Green Senior Preferred Notes by BOC PCL
24th Apr 20247:00 amRNSBOCH - Transaction in Own Shares
24th Apr 20247:00 amRNSTR1 Notification - Helikon
24th Apr 20247:00 amRNSTR1 Notification -Helikon
23rd Apr 20247:25 amRNSBOCH - Transactions in Own Shares
22nd Apr 20247:27 amRNSBOCH - Transactions in Own Shares
19th Apr 20247:41 amRNSLaunch of share buyback programme
12th Apr 202410:02 amRNSNotice of AGM
5th Apr 20247:20 amRNS2023 Pillar 3 Disclosures
2nd Apr 20241:21 pmRNSTR1 Notification of Holdings - OSOME
2nd Apr 202412:59 pmRNSTR1 Notification of Holdings - OSOME
28th Mar 20242:24 pmRNSBOC Annual Financial Report 2023 Announcement
28th Mar 20241:31 pmRNSBOCH Annual Financial Report 2023 Announcement
28th Mar 20241:30 pmRNSFY2023 Investor Presentation Announcement
28th Mar 20241:30 pmRNSFY2023 Group Financial Results
20th Mar 20247:00 amRNSAnnouncement of Distribution
15th Mar 20249:21 amRNSDate of Announcement of Audited FY2023 FS
19th Feb 20247:01 amRNSDoc re. (Prelim FY2023 Investor Presentation)
19th Feb 20247:00 amRNSPreliminary FY2023 Group Financial Results
6th Feb 20248:41 amRNSDate of announcement of Preliminary FY2023 FR
22nd Dec 20239:09 amRNSRevised Date of AGM
20th Dec 20238:32 amRNSChanges in the composition of the BOD & Committees
13th Dec 20237:00 amRNSEU-wide Transparency Exercise 2023
11th Dec 20232:51 pmRNSChanges in the composition of the BOD
29th Nov 202310:28 amRNSDecision to call AT1 Capital Securities
29th Nov 20238:19 amRNSDate of Annual General Meeting
20th Nov 20239:58 amRNSAppointment of New Director
13th Nov 20237:00 amRNSDoc re. (9M2023 Investor Presentation)
13th Nov 20237:00 amRNS9M2023 Group Financial Results
27th Oct 20237:17 amRNSDate of announcement of 9M2023 FR
24th Oct 202312:41 pmRNSTR1 Notification - Caius
13th Oct 202312:27 pmRNSChanges in the composition of the BODs
27th Sep 20238:28 amRNSDirectorate Change
31st Aug 20237:37 amRNSChanges in the composition of BOD
11th Aug 20239:55 amRNSAppointment of new director
21st Jul 202310:43 amRNSDate of announcement of 1H2023 FR
18th Jul 20234:43 pmRNSIssue of Senior Preferred Notes
3rd Jul 202311:48 amRNSBuyback of Additional Tier 1 Capital Securities
23rd Jun 202312:48 pmRNSComposition of the Boards of Directors
20th Jun 202312:22 pmRNSResults of Additional Tier 1 Tender Cash Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.